Concepts (327)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cognition | 49 | 2023 | 1378 | 7.860 |
Why?
|
| Brain | 39 | 2023 | 1696 | 4.890 |
Why?
|
| White Matter | 11 | 2022 | 142 | 4.720 |
Why?
|
| Aging | 35 | 2023 | 1578 | 4.570 |
Why?
|
| Cognitive Dysfunction | 32 | 2023 | 1073 | 3.980 |
Why?
|
| Aged | 116 | 2023 | 9344 | 3.720 |
Why?
|
| Alzheimer Disease | 30 | 2023 | 2144 | 3.520 |
Why?
|
| Neuropsychological Tests | 60 | 2023 | 1255 | 3.470 |
Why?
|
| Cardiovascular Diseases | 13 | 2023 | 373 | 3.300 |
Why?
|
| Diffusion Tensor Imaging | 12 | 2023 | 67 | 2.780 |
Why?
|
| Magnetic Resonance Imaging | 35 | 2023 | 1197 | 2.670 |
Why?
|
| Cognition Disorders | 18 | 2020 | 1019 | 2.620 |
Why?
|
| Humans | 143 | 2023 | 28554 | 2.560 |
Why?
|
| Female | 100 | 2023 | 15821 | 2.480 |
Why?
|
| Male | 97 | 2023 | 15401 | 2.450 |
Why?
|
| Hypertension | 7 | 2022 | 244 | 2.360 |
Why?
|
| Depression | 8 | 2020 | 454 | 2.240 |
Why?
|
| Executive Function | 21 | 2023 | 116 | 2.190 |
Why?
|
| Middle Aged | 70 | 2023 | 9322 | 2.060 |
Why?
|
| Blood Pressure | 8 | 2022 | 207 | 1.980 |
Why?
|
| Aged, 80 and over | 53 | 2023 | 4901 | 1.870 |
Why?
|
| Verbal Learning | 11 | 2021 | 37 | 1.830 |
Why?
|
| Dementia | 16 | 2023 | 582 | 1.780 |
Why?
|
| Acculturation | 3 | 2023 | 37 | 1.740 |
Why?
|
| Memory, Short-Term | 11 | 2023 | 103 | 1.710 |
Why?
|
| Connectome | 5 | 2021 | 12 | 1.710 |
Why?
|
| Diet, Mediterranean | 5 | 2023 | 101 | 1.710 |
Why?
|
| Risk Factors | 26 | 2023 | 2414 | 1.600 |
Why?
|
| Gray Matter | 5 | 2023 | 55 | 1.570 |
Why?
|
| Prefrontal Cortex | 7 | 2016 | 149 | 1.540 |
Why?
|
| Neuroimaging | 10 | 2023 | 133 | 1.500 |
Why?
|
| Health Literacy | 3 | 2023 | 109 | 1.450 |
Why?
|
| Memory Disorders | 6 | 2018 | 171 | 1.410 |
Why?
|
| Cerebrovascular Disorders | 4 | 2021 | 133 | 1.390 |
Why?
|
| Residence Characteristics | 4 | 2021 | 214 | 1.320 |
Why?
|
| Decision Making | 6 | 2023 | 229 | 1.280 |
Why?
|
| Arteriolosclerosis | 3 | 2023 | 78 | 1.190 |
Why?
|
| Public Health | 6 | 2021 | 67 | 1.180 |
Why?
|
| Brain Mapping | 9 | 2021 | 167 | 1.160 |
Why?
|
| Mental Status and Dementia Tests | 4 | 2021 | 70 | 1.090 |
Why?
|
| United States | 18 | 2021 | 2191 | 1.070 |
Why?
|
| Depressive Disorder | 5 | 2017 | 184 | 1.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2018 | 185 | 1.030 |
Why?
|
| Nerve Fibers, Myelinated | 5 | 2013 | 29 | 1.030 |
Why?
|
| Depressive Disorder, Major | 9 | 2018 | 103 | 1.020 |
Why?
|
| Cohort Studies | 18 | 2023 | 1942 | 1.020 |
Why?
|
| Memory | 10 | 2021 | 311 | 1.000 |
Why?
|
| Apolipoproteins E | 4 | 2023 | 253 | 0.990 |
Why?
|
| Cognitive Aging | 3 | 2020 | 79 | 0.950 |
Why?
|
| Stroke | 5 | 2023 | 276 | 0.950 |
Why?
|
| Exercise | 7 | 2022 | 472 | 0.940 |
Why?
|
| Cross-Sectional Studies | 14 | 2023 | 934 | 0.930 |
Why?
|
| Hippocampus | 9 | 2022 | 283 | 0.920 |
Why?
|
| Educational Status | 5 | 2023 | 297 | 0.910 |
Why?
|
| Tryptophan | 4 | 2012 | 9 | 0.900 |
Why?
|
| Psychomotor Performance | 9 | 2020 | 213 | 0.900 |
Why?
|
| Pattern Recognition, Visual | 2 | 2019 | 27 | 0.890 |
Why?
|
| Diabetes Mellitus | 3 | 2020 | 137 | 0.880 |
Why?
|
| Linear Models | 6 | 2020 | 255 | 0.860 |
Why?
|
| Spatial Processing | 2 | 2021 | 7 | 0.860 |
Why?
|
| Mental Recall | 7 | 2020 | 71 | 0.820 |
Why?
|
| Income | 3 | 2021 | 78 | 0.820 |
Why?
|
| Genotype | 5 | 2020 | 359 | 0.800 |
Why?
|
| Social Participation | 1 | 2022 | 12 | 0.800 |
Why?
|
| Adult | 26 | 2023 | 8173 | 0.790 |
Why?
|
| Blood Glucose | 2 | 2022 | 108 | 0.780 |
Why?
|
| Crime Victims | 1 | 2022 | 33 | 0.780 |
Why?
|
| Clinical Protocols | 1 | 2022 | 60 | 0.760 |
Why?
|
| Anisotropy | 5 | 2023 | 53 | 0.760 |
Why?
|
| Longitudinal Studies | 13 | 2023 | 1397 | 0.730 |
Why?
|
| Optimism | 1 | 2021 | 2 | 0.730 |
Why?
|
| Cerebral Cortex | 4 | 2021 | 165 | 0.730 |
Why?
|
| Psychology | 1 | 2021 | 24 | 0.730 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2018 | 191 | 0.720 |
Why?
|
| Family Relations | 1 | 2021 | 14 | 0.720 |
Why?
|
| Social Segregation | 1 | 2020 | 7 | 0.710 |
Why?
|
| Social Environment | 1 | 2021 | 83 | 0.700 |
Why?
|
| Dementia, Vascular | 5 | 2020 | 45 | 0.700 |
Why?
|
| Racism | 1 | 2021 | 32 | 0.700 |
Why?
|
| Antihypertensive Agents | 2 | 2020 | 81 | 0.690 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2022 | 88 | 0.690 |
Why?
|
| Cholesterol | 2 | 2019 | 64 | 0.690 |
Why?
|
| Social Capital | 1 | 2020 | 4 | 0.680 |
Why?
|
| Loneliness | 1 | 2021 | 63 | 0.680 |
Why?
|
| Analysis of Variance | 9 | 2017 | 276 | 0.670 |
Why?
|
| Triglycerides | 1 | 2019 | 61 | 0.660 |
Why?
|
| Dyslipidemias | 1 | 2019 | 18 | 0.650 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 53 | 0.650 |
Why?
|
| Social Support | 1 | 2021 | 215 | 0.640 |
Why?
|
| Life Style | 1 | 2021 | 201 | 0.640 |
Why?
|
| Hyperinsulinism | 1 | 2019 | 4 | 0.640 |
Why?
|
| Mental Processes | 1 | 2019 | 20 | 0.630 |
Why?
|
| Cultural Diversity | 1 | 2019 | 29 | 0.620 |
Why?
|
| Insulin Resistance | 1 | 2019 | 52 | 0.620 |
Why?
|
| Community Health Services | 1 | 2019 | 35 | 0.620 |
Why?
|
| Prospective Studies | 13 | 2022 | 1811 | 0.610 |
Why?
|
| Neural Pathways | 9 | 2018 | 73 | 0.610 |
Why?
|
| Multilingualism | 1 | 2019 | 21 | 0.610 |
Why?
|
| Stress, Psychological | 1 | 2021 | 242 | 0.610 |
Why?
|
| Independent Living | 6 | 2022 | 320 | 0.610 |
Why?
|
| Phenotype | 2 | 2019 | 311 | 0.600 |
Why?
|
| Kidney | 1 | 2019 | 175 | 0.590 |
Why?
|
| Psychological Trauma | 1 | 2017 | 4 | 0.570 |
Why?
|
| Affect | 3 | 2013 | 62 | 0.540 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 45 | 0.530 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 392 | 0.530 |
Why?
|
| Individuality | 1 | 2016 | 25 | 0.520 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2023 | 190 | 0.500 |
Why?
|
| Metabolic Diseases | 1 | 2015 | 10 | 0.480 |
Why?
|
| Psychomotor Disorders | 1 | 2014 | 11 | 0.470 |
Why?
|
| Thinking | 1 | 2014 | 18 | 0.470 |
Why?
|
| Verbal Behavior | 5 | 2009 | 18 | 0.470 |
Why?
|
| Obesity | 4 | 2023 | 322 | 0.450 |
Why?
|
| Sex Factors | 6 | 2020 | 477 | 0.450 |
Why?
|
| Age Factors | 8 | 2020 | 789 | 0.440 |
Why?
|
| Surveys and Questionnaires | 10 | 2021 | 1213 | 0.440 |
Why?
|
| Frontal Lobe | 5 | 2018 | 83 | 0.430 |
Why?
|
| Vascular Diseases | 2 | 2013 | 44 | 0.430 |
Why?
|
| Memory, Episodic | 3 | 2018 | 116 | 0.420 |
Why?
|
| Serotonin | 3 | 2012 | 24 | 0.420 |
Why?
|
| Health Surveys | 4 | 2021 | 88 | 0.410 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2012 | 37 | 0.410 |
Why?
|
| Leukoaraiosis | 2 | 2012 | 7 | 0.410 |
Why?
|
| Alleles | 4 | 2023 | 221 | 0.400 |
Why?
|
| Models, Statistical | 3 | 2021 | 129 | 0.400 |
Why?
|
| Attention | 6 | 2023 | 138 | 0.400 |
Why?
|
| Galvanic Skin Response | 1 | 2011 | 7 | 0.390 |
Why?
|
| Gambling | 1 | 2011 | 8 | 0.380 |
Why?
|
| Case-Control Studies | 9 | 2023 | 599 | 0.380 |
Why?
|
| Models, Psychological | 1 | 2011 | 77 | 0.370 |
Why?
|
| Dancing | 2 | 2021 | 14 | 0.370 |
Why?
|
| Down Syndrome | 1 | 2011 | 10 | 0.370 |
Why?
|
| Brain Chemistry | 1 | 2011 | 44 | 0.360 |
Why?
|
| Biomarkers | 4 | 2021 | 601 | 0.360 |
Why?
|
| Crime | 2 | 2021 | 7 | 0.360 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2023 | 181 | 0.360 |
Why?
|
| Basal Ganglia Cerebrovascular Disease | 1 | 2010 | 3 | 0.340 |
Why?
|
| Sex Characteristics | 2 | 2022 | 121 | 0.330 |
Why?
|
| Imaging, Three-Dimensional | 3 | 2016 | 235 | 0.330 |
Why?
|
| Chicago | 3 | 2021 | 942 | 0.330 |
Why?
|
| Apolipoprotein E4 | 3 | 2020 | 264 | 0.300 |
Why?
|
| Psychiatric Status Rating Scales | 7 | 2017 | 327 | 0.300 |
Why?
|
| Neural Inhibition | 1 | 2007 | 7 | 0.290 |
Why?
|
| Myelin Sheath | 2 | 2021 | 26 | 0.290 |
Why?
|
| Amnesia | 5 | 2020 | 27 | 0.280 |
Why?
|
| Learning | 2 | 2018 | 71 | 0.280 |
Why?
|
| Self Report | 3 | 2023 | 226 | 0.270 |
Why?
|
| Principal Component Analysis | 3 | 2021 | 26 | 0.270 |
Why?
|
| Language | 3 | 2021 | 69 | 0.270 |
Why?
|
| Hospitalization | 2 | 2019 | 323 | 0.270 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 732 | 0.260 |
Why?
|
| Nerve Net | 5 | 2018 | 46 | 0.260 |
Why?
|
| Prevalence | 4 | 2021 | 467 | 0.260 |
Why?
|
| Pilot Projects | 3 | 2022 | 438 | 0.260 |
Why?
|
| DNA-Binding Proteins | 3 | 2023 | 274 | 0.250 |
Why?
|
| Problem Solving | 2 | 2009 | 47 | 0.240 |
Why?
|
| Temporal Lobe | 3 | 2018 | 87 | 0.230 |
Why?
|
| Discrimination Learning | 1 | 2004 | 1 | 0.230 |
Why?
|
| Color Perception | 1 | 2004 | 5 | 0.230 |
Why?
|
| Models, Neurological | 3 | 2018 | 25 | 0.230 |
Why?
|
| Young Adult | 5 | 2021 | 2104 | 0.220 |
Why?
|
| Arousal | 1 | 2004 | 50 | 0.220 |
Why?
|
| Severity of Illness Index | 5 | 2017 | 990 | 0.220 |
Why?
|
| Reaction Time | 5 | 2023 | 114 | 0.210 |
Why?
|
| Postmenopause | 1 | 2023 | 55 | 0.210 |
Why?
|
| Time Factors | 2 | 2019 | 1498 | 0.210 |
Why?
|
| Intelligence Tests | 2 | 2015 | 15 | 0.200 |
Why?
|
| Research Design | 2 | 2021 | 207 | 0.200 |
Why?
|
| Fraud | 1 | 2022 | 21 | 0.200 |
Why?
|
| Atherosclerosis | 1 | 2023 | 56 | 0.200 |
Why?
|
| Psychometrics | 2 | 2021 | 244 | 0.190 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 520 | 0.190 |
Why?
|
| Socioeconomic Factors | 2 | 2021 | 309 | 0.190 |
Why?
|
| Geriatric Assessment | 3 | 2017 | 214 | 0.190 |
Why?
|
| Regression Analysis | 5 | 2018 | 270 | 0.190 |
Why?
|
| Awareness | 1 | 2002 | 45 | 0.190 |
Why?
|
| Facial Expression | 2 | 2012 | 15 | 0.190 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2023 | 114 | 0.190 |
Why?
|
| Data Interpretation, Statistical | 3 | 2022 | 84 | 0.180 |
Why?
|
| Social Identification | 1 | 2021 | 8 | 0.180 |
Why?
|
| Social Networking | 1 | 2021 | 11 | 0.180 |
Why?
|
| Accelerometry | 2 | 2021 | 87 | 0.180 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2021 | 12 | 0.180 |
Why?
|
| Adolescent | 5 | 2021 | 2323 | 0.180 |
Why?
|
| Emotions | 2 | 2012 | 87 | 0.180 |
Why?
|
| Southeastern United States | 1 | 2020 | 14 | 0.180 |
Why?
|
| Treatment Outcome | 2 | 2022 | 3622 | 0.170 |
Why?
|
| Midwestern United States | 1 | 2020 | 62 | 0.170 |
Why?
|
| Organ Size | 3 | 2023 | 106 | 0.170 |
Why?
|
| Wechsler Scales | 3 | 2006 | 10 | 0.170 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2022 | 329 | 0.170 |
Why?
|
| Space Perception | 1 | 2020 | 24 | 0.170 |
Why?
|
| Visual Perception | 1 | 2020 | 34 | 0.170 |
Why?
|
| Judgment | 1 | 2019 | 9 | 0.170 |
Why?
|
| Cholesterol, HDL | 1 | 2019 | 28 | 0.170 |
Why?
|
| Acute Disease | 2 | 2012 | 208 | 0.170 |
Why?
|
| Cholesterol, LDL | 1 | 2019 | 32 | 0.170 |
Why?
|
| Disabled Persons | 1 | 2021 | 125 | 0.160 |
Why?
|
| Patient Selection | 1 | 2021 | 207 | 0.160 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 333 | 0.160 |
Why?
|
| Interpersonal Relations | 1 | 2020 | 104 | 0.160 |
Why?
|
| Genome-Wide Association Study | 1 | 2020 | 291 | 0.160 |
Why?
|
| Pandemics | 1 | 2021 | 262 | 0.160 |
Why?
|
| Hypercholesterolemia | 1 | 2019 | 27 | 0.160 |
Why?
|
| Atrophy | 2 | 2016 | 94 | 0.160 |
Why?
|
| Financing, Personal | 1 | 2018 | 20 | 0.160 |
Why?
|
| Emergencies | 1 | 2019 | 36 | 0.160 |
Why?
|
| Follow-Up Studies | 6 | 2019 | 1863 | 0.150 |
Why?
|
| Energy Intake | 1 | 2019 | 82 | 0.150 |
Why?
|
| Cognitive Reserve | 1 | 2019 | 39 | 0.150 |
Why?
|
| Genetic Variation | 1 | 2018 | 100 | 0.150 |
Why?
|
| Heterozygote | 1 | 2018 | 102 | 0.150 |
Why?
|
| Healthy Aging | 1 | 2017 | 14 | 0.140 |
Why?
|
| Healthy Lifestyle | 1 | 2017 | 46 | 0.140 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2016 | 19 | 0.140 |
Why?
|
| Phobia, Social | 1 | 2016 | 13 | 0.130 |
Why?
|
| Motor Skills | 1 | 2017 | 53 | 0.130 |
Why?
|
| Neurodegenerative Diseases | 1 | 2018 | 124 | 0.130 |
Why?
|
| Self-Assessment | 2 | 2020 | 30 | 0.130 |
Why?
|
| HIV Infections | 1 | 2021 | 490 | 0.130 |
Why?
|
| Prognosis | 1 | 2019 | 827 | 0.130 |
Why?
|
| Gyrus Cinguli | 2 | 2016 | 17 | 0.130 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 170 | 0.130 |
Why?
|
| Bipolar Disorder | 1 | 2016 | 132 | 0.130 |
Why?
|
| Urban Population | 1 | 2017 | 158 | 0.130 |
Why?
|
| Parkinson Disease | 2 | 2020 | 846 | 0.120 |
Why?
|
| Cytokines | 1 | 2017 | 232 | 0.120 |
Why?
|
| Cerebrovascular Circulation | 2 | 2014 | 35 | 0.120 |
Why?
|
| Double-Blind Method | 2 | 2012 | 433 | 0.120 |
Why?
|
| Inflammation | 3 | 2023 | 288 | 0.120 |
Why?
|
| Macromolecular Substances | 1 | 2014 | 6 | 0.120 |
Why?
|
| Statistics as Topic | 1 | 2014 | 112 | 0.120 |
Why?
|
| Animals | 2 | 2013 | 3814 | 0.110 |
Why?
|
| Axons | 1 | 2013 | 28 | 0.110 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2016 | 235 | 0.110 |
Why?
|
| Oxygen | 1 | 2012 | 81 | 0.100 |
Why?
|
| Autistic Disorder | 1 | 2012 | 41 | 0.100 |
Why?
|
| Language Tests | 2 | 2021 | 33 | 0.100 |
Why?
|
| Task Performance and Analysis | 1 | 2011 | 49 | 0.090 |
Why?
|
| Reward | 1 | 2011 | 27 | 0.090 |
Why?
|
| Social Class | 2 | 2022 | 67 | 0.090 |
Why?
|
| Inositol | 1 | 2011 | 6 | 0.090 |
Why?
|
| Aspartic Acid | 1 | 2011 | 14 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 42 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 623 | 0.090 |
Why?
|
| Syndrome | 1 | 2010 | 82 | 0.080 |
Why?
|
| Weight Loss | 2 | 2023 | 130 | 0.080 |
Why?
|
| Mental Status Schedule | 2 | 2011 | 97 | 0.080 |
Why?
|
| Medicare | 2 | 2019 | 121 | 0.080 |
Why?
|
| Cues | 2 | 2011 | 50 | 0.080 |
Why?
|
| Neuropathology | 2 | 2019 | 84 | 0.070 |
Why?
|
| Comorbidity | 1 | 2009 | 500 | 0.070 |
Why?
|
| Adaptation, Physiological | 1 | 2007 | 53 | 0.070 |
Why?
|
| Cluster Analysis | 2 | 2011 | 44 | 0.070 |
Why?
|
| Functional Laterality | 1 | 2007 | 68 | 0.070 |
Why?
|
| Lewy Bodies | 2 | 2019 | 194 | 0.070 |
Why?
|
| Reading | 1 | 2006 | 42 | 0.070 |
Why?
|
| Dominance, Cerebral | 1 | 2004 | 16 | 0.060 |
Why?
|
| Evoked Potentials | 1 | 2004 | 14 | 0.060 |
Why?
|
| Limbic System | 1 | 2004 | 8 | 0.060 |
Why?
|
| Reproduction | 1 | 2023 | 10 | 0.050 |
Why?
|
| Estrogens | 1 | 2023 | 25 | 0.050 |
Why?
|
| Baltimore | 1 | 2003 | 9 | 0.050 |
Why?
|
| Sample Size | 1 | 2003 | 20 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 54 | 0.050 |
Why?
|
| Age of Onset | 2 | 2013 | 98 | 0.050 |
Why?
|
| Infarction | 1 | 2023 | 30 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2023 | 32 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 201 | 0.050 |
Why?
|
| Maze Learning | 1 | 2002 | 16 | 0.050 |
Why?
|
| Boston | 1 | 2022 | 27 | 0.050 |
Why?
|
| Cholinergic Antagonists | 1 | 2022 | 11 | 0.050 |
Why?
|
| Physical Therapy Modalities | 1 | 2022 | 75 | 0.050 |
Why?
|
| Pregnancy | 1 | 2023 | 341 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2021 | 13 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 154 | 0.050 |
Why?
|
| Psychotic Disorders | 1 | 2002 | 47 | 0.050 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 34 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 496 | 0.050 |
Why?
|
| Probability | 1 | 2021 | 92 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 1 | 2021 | 63 | 0.050 |
Why?
|
| Caribbean Region | 1 | 2020 | 3 | 0.050 |
Why?
|
| South America | 1 | 2020 | 3 | 0.050 |
Why?
|
| Information Dissemination | 1 | 2021 | 20 | 0.040 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 1 | 2020 | 5 | 0.040 |
Why?
|
| Lung | 1 | 2021 | 170 | 0.040 |
Why?
|
| New York | 1 | 2020 | 10 | 0.040 |
Why?
|
| Florida | 1 | 2020 | 22 | 0.040 |
Why?
|
| California | 1 | 2020 | 32 | 0.040 |
Why?
|
| Orientation | 1 | 2020 | 6 | 0.040 |
Why?
|
| Photic Stimulation | 1 | 2020 | 35 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2019 | 13 | 0.040 |
Why?
|
| Walking | 1 | 2022 | 261 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2020 | 59 | 0.040 |
Why?
|
| Cerebral Ventricles | 1 | 2019 | 19 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2019 | 35 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 373 | 0.040 |
Why?
|
| Amyloid | 1 | 2018 | 57 | 0.040 |
Why?
|
| Lewy Body Disease | 1 | 2019 | 100 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 722 | 0.040 |
Why?
|
| Amygdala | 1 | 2018 | 42 | 0.040 |
Why?
|
| Serial Learning | 1 | 2018 | 7 | 0.040 |
Why?
|
| Nervous System Diseases | 1 | 2019 | 121 | 0.040 |
Why?
|
| Health Status | 1 | 2019 | 226 | 0.040 |
Why?
|
| Perception | 1 | 2018 | 78 | 0.040 |
Why?
|
| Comoros | 1 | 2017 | 1 | 0.040 |
Why?
|
| Caloric Restriction | 1 | 2017 | 16 | 0.040 |
Why?
|
| Neurofibrillary Tangles | 1 | 2018 | 194 | 0.040 |
Why?
|
| Sphygmomanometers | 1 | 2017 | 4 | 0.030 |
Why?
|
| Massachusetts | 1 | 2017 | 19 | 0.030 |
Why?
|
| Autopsy | 1 | 2018 | 346 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 56 | 0.030 |
Why?
|
| tau Proteins | 1 | 2018 | 235 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 79 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 192 | 0.030 |
Why?
|
| Czech Republic | 1 | 2014 | 1 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2014 | 30 | 0.030 |
Why?
|
| Thalamus | 1 | 2014 | 16 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2017 | 467 | 0.030 |
Why?
|
| Corpus Striatum | 1 | 2014 | 65 | 0.030 |
Why?
|
| Semantics | 1 | 2014 | 19 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2012 | 63 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2011 | 90 | 0.020 |
Why?
|
| Amino Acids | 1 | 2010 | 17 | 0.020 |
Why?
|
| Disability Evaluation | 1 | 2009 | 291 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 89 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2011 | 3615 | 0.010 |
Why?
|